echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Hepatol: Telomerase, a new potential therapeutic target for liver stage!

    J Hepatol: Telomerase, a new potential therapeutic target for liver stage!

    • Last Update: 2021-01-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Telomerase activation is the earliest event in the development of hepatocellular carcinoma (HCC).
    telomere length (TL) is regulated by telomere complexes consisting of TRT (telomere reverse transcriptase), TERC (telomere RNA components), and a variety of proteins.
    study aims to clarify the change and regulation of telomere length in the course of liver cancer.
    researchers measured telomere length in tumor tissue and non-tumor tissue in 1,502 patients (978 cases of HCC) and analyzed the correlation between TRT variation and expression with the clinical and molecular characteristics of liver cancer by genome, exon group, target or RNA sequencing.
    , preclinical activity against TTERT antispoy oligonucleotides (ASOs) was evaluated in 26 cell line and transplanted tumor mouse models.
    liver telomere length and age, fibrosis, age associated with male and alcohol intake, liver fibrosis, male and excessive alcohol intake are independent determinates of liver telomere consumption.
    developed by livers with long telomeres are usually TRT wild types with ancestral cell characteristics and BAP1 mutations.
    , the HCC developed by livers with short telomeres is mostly non-proliferating HCC, and the multi-rich system TRT initiater mutation.
    TERT over-expression and long telomeres associated with HCC invasion HCC can activate TRT expression through a variety of mechanisms to stabilize telomere length at 5.7Kb, in a narrow biological range, similar to a non-tumor liver.
    in tumors, long telomeres are characteristic of strong invasive HCC and are associated with G3 transcription subtypes, TP53 variants, and poor prognosmology.
    anti-tumor activity of anti-TERT ASO is found in HCC cell line, and the use of antisant oligonucleotide chain silencing TRT is effective in cells with high proliferation and poor differentiation.
    after 3-16 weeks of treatment with an antisemisive oligonucleotide chain, cell proliferation stagnation was successfully induced in 12 cell linelets by shortening telomere length, DNA damage, and apoptosis activation.
    antisant oligonucleotide chain also obtained therapeutic effect in transplanted tumor mouse models.
    , telomere lengths are varied during the occurrence of HCC tumors and are associated with tumor progression and invasiveness.
    the activity of anti-TTERT ASO in HCC cell line reveals the tumor-like and anti-TTERT ASO preclinical basis for entering HCC clinical trials.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.